Pharmaceutical Companies
How do pharmaceutical companies manage medicine VAT rates and clinical trial invoicing?
Pharmaceutical companies sell products across multiple VAT rate categories: prescription medicines at zero or reduced rates in most jurisdictions, over-the-counter medicines at reduced or standard rates, medical devices at varying rates, and clinical trial materials which may have complex VAT treatment. Invoicing compliance requires accurate product classification, rate assignment, and structured format compliance for large B2B transactions with hospitals and distributors.
How do VAT rates apply to pharmaceutical products?
Pharmaceutical product VAT rates vary significantly by jurisdiction and product type:
- UK: Prescription medicines zero-rated; OTC medicines standard rated at 20 percent
- France: Human medicines at 2.1 percent super-reduced rate; OTC at 10 percent reduced rate
- Germany: Prescription and most medicines at 7 percent reduced rate; medical devices at 19 percent standard rate
- UAE: Most healthcare products at 5 percent; specified basic medicines at 0 percent
- Ireland: Oral medicines zero-rated; topical medicines standard rated; medical devices varying rates
- EU general: Wide variation; companies must maintain product-level VAT rate tables per jurisdiction
Frequently Asked Questions
- How is VAT applied to clinical trial materials?
- Clinical trial materials (investigational medicinal products) have complex VAT treatment. In many jurisdictions, supply of trial materials to sponsors for use in clinical trials may be outside scope or VAT-exempt where no commercial supply is made. However, contract research organization services are taxable. Companies must analyze whether each clinical trial supply constitutes a taxable supply or is outside scope, and invoice accordingly.
- How do pharmaceutical companies invoice hospitals for bulk drug supplies?
- Hospital bulk pharmaceutical purchases are B2B transactions requiring full VAT invoices. In mandated jurisdictions, structured e-invoice formats (UBL, Factur-X) are required for invoicing public hospitals which fall under public sector e-invoicing requirements. Pharmaceutical companies must be able to issue Peppol-compatible invoices to public health authorities in EU member states. Product identification using GS1 codes or national drug codes aids automated matching.